Funder: Eli Lilly and Company
Due Dates: February 15, 2026: Efficacy of Lebrikizumab in fibrosing skin conditions | February 15, 2026: Lebrikizumab and post-inflammatory dyspigmentation in atopic dermatitis | June 15, 2026: Real-world effectiveness of mirkizumab in IBD (Canada)
Funding Amounts: Funding level varies by project; typically includes financial support and/or provision of study drug for approved proposals.
Summary: Supports independent, investigator-initiated clinical research aligned with Lilly’s posted RFPs in selected therapeutic areas.
Key Information: Proposals must address posted RFP focus areas and be submitted by the specified deadlines.